Logo

Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease

Share this
Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease

Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease

Shots:

  • Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on sales globally & holds the rights for research- preclinical- diagnostic & other non-therapeutic applications of Xork
  • The collaboration will utilize Genovis’ IgG protease- IdeXork (Xork & Selecta’s ImmTOR platform for transformative gene therapies to treat patients with AAV immunity & IgG-mediated autoimmune diseases
  • Selecta obtains an exclusive WW right to Xork. The combination of Xork & ImmTOR has the potential to mitigate pre-existing Abs to AAV- expand access to gene therapy- prevent de novo immunogenicity & enable re-dosing of Xork

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: Selectabio


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family